On September 10, 2025, Wilson Sonsini's Eva Yin, Partner, and Matthew Meyer, Chief Business Advisor, will participate in the “From Lab to Launch” webinar, hosted by GenoSan. Eva will present on FDA regulatory pathways and compliance considerations for diagnostics companies entering the U.S. market. Matthew will offer insights on how life sciences startups can effectively pitch to venture capital firms, drawing on his experience advising diagnostics and biopharma companies. The webinar is designed for innovators, entrepreneurs and industry executives preparing to bring new diagnostic technologies to market. For more information about the event, you can visit the event website.
Hannah Hebertson
hhebertson@wsgr.com
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
Matthew J. Meyer is chief business advisor for life sciences at Wilson Sonsini Goodrich & Rosati. Based in San Francisco, Matthew leads the firm's life science business advisory practice—a newly formed, innovative resource aimed at providing start-up and emerging life sciences companies with business insights, capabilities, and strategies to help them thrive and address some of their most challenging issues.